Recent Reports

ICER’s Draft Evidence Report on treatments for hereditary transthyretin-related amyloidosis, open to public comment until August 17, 2018 at 5pm ET. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic

ICER’s Draft Evidence Report on treatments for high risk prostate cancer, open to public comment until August 9, 2018. For more information on submitting a public comment, please visit our stakeholder engagement page.

View More on this Topic



Materials

Midwest CEPAC

Asthma: Model Analysis Plan

New England CEPAC

Plaque Psoriasis: Report-at-a-Glance

New England CEPAC

Endometriosis: Report-at-a-Glance

New England CEPAC

Opioid Use Disorder: Model Analysis Plan

Midwest CEPAC

Asthma: Research Protocol

Midwest CEPAC

Atherosclerosis: Open Input Period

New England CEPAC

Endometriosis: Evidence Presentation

New England CEPAC

Psoriasis Update: Evidence Presentation

CTAF

Migraine: Report-at-a-Glance

CTAF

Hereditary Angioedema: Model Analysis Plan

New England CEPAC

Opioid Use Disorder: Research Protocol

Midwest CEPAC

Atherosclerosis: Draft Scoping Document